Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-01

Study Completion Date

2021-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To analyze and evaluate the efficacy and safety of octreotide subcutaneous injection in the treatment of diazazine-ineffective congenital hyperinsulinemia (CHI) in children.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Octreotide subcutaneous injection is effective and safe in the treatment of congenital hyperinsulinemia in children with inefficacy of diazazine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Hyperinsulinaemic Hypoglycaemia Octreotide Adverse Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Octreotide Injection

Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

glucose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Consistent with the diagnosis of congenital hyperinsulinemia with ineffective diazine; With the maximum dose of diazine at 15mg/kg/d for 5 days, fasting blood glucose/postprandial blood glucose could not be stabilized at the target value of 3.3mmol/L without intravenous glucose infusion.
2. patients treated with octreotide subcutaneous injection.

Exclusion Criteria

1. Before the diagnosis of CHI and the treatment related to CHI, the child had received total pancreatectomy without octreotide
2. Secondary hypoglycemia caused by diseases other than CHI
3. Patients who refused to take octreotide due to parents or family economic reasons, but not hospital treatment factors.
4. Patients who intervene/interfere with octreotide treatment regimen for parental reasons

Minimum Eligible Age

1 Month

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chunxiu Gong

director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

bingyan cao, doctor

Role: PRINCIPAL_INVESTIGATOR

doctor of Beijing children's hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Endocrinology, Genetics, Metabolism

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

octreotide-CHI-2021

Identifier Type: -

Identifier Source: org_study_id